AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t
Sarah Rickwood delves into IQVIA data to find out exactly how pharma's HCP engagement has changed over COVID-19, and what the channel mix might look like after the pandemic.